The Week

Eli Lilly (LLY) fell 2.15% this week to close at $1,149.36, lagging the S&P 500, which added 0.09%, by about 2.24 percentage points. The stock opened Monday at $1,168.47, briefly touched a weekly high of $1,188.325 on Tuesday, then drifted lower over the next three sessions. Thursday brought the weekly low at $1,137.50, and Friday closed at $1,149.36. Weekly amplitude was 4.35%, and average daily volume of 2.56m shares sat about 2.1% below the 60-day median, a muted turnover picture.

Key Events

The week’s story centred on deal-making and label expansion. On Monday, Lilly announced it would acquire Merida Biosciences for up to $2.88bn, moving into severe autoimmune and allergic diseases. The same day, Phase 3b data for Taltz combined with Zepbound showed durable efficacy at week 52 in adults with psoriatic disease and obesity. On Tuesday, the FDA approved tirzepatide for cardiovascular risk reduction in type 2 diabetes, and the Atai Beckley merger cleared its US antitrust waiting period. Lilly is also set to participate in the Morgan Stanley Global Healthcare Conference, while Jefferies and JPMorgan Chase reiterated or issued buy ratings this week. Broader industry news included US drug pricing deals with nine manufacturers and Novo Nordisk’s launch of oral Wegovy in Germany.

Analyst Ratings

Among 32 firms covering Lilly, 18 rate it buy, 6 rate it overweight, 4 rate it hold, 1 rates it underweight, 1 rates it sell, and 2 have no opinion. That leaves 24 at buy or overweight and 2 at underweight or sell. The consensus rating is buy, with a consensus target price of $1,315.55793, about 14.5% above the latest close of $1,149.36. Target prices range from $850 to $1,600, a wide spread that reflects a meaningful divergence. Lilly ranks first within its pharmaceutical industry coverage of 205 firms.

The Week Ahead

Macro data picks up next week: Tuesday brings the NFIB small business optimism index, while Thursday includes initial jobless claims, several PPI prints, existing home sales and a 10-year Treasury auction. Lilly’s Q3 2026 earnings are scheduled for 29 October, outside the immediate window. Worth following are any updates on the Merida transaction and the wider read-through from US drug pricing agreements for large-cap pharma.

In Short

Lilly’s pullback this week ran against the broader market’s modest gain, with light volume suggesting a consolidation after prior strength rather than a forceful sell-off. The sell-side consensus still sits at buy with a target roughly 14.5% above spot, but the $750-wide target range shows that conviction is far from uniform. The latest session’s order flow pointed to heavier small-lot selling without clear large-lot accumulation. The next real test is the Q3 print in late October, along with how the shifting pricing environment feeds into valuation.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.